Author of

• 25520

  +

  Poster Display session (Friday) (ID 65)

  • Event: ELCC 2018
  • Type: Poster Display session
  • Track:
  • Presentations: 2
  • Moderators:
  • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1

  • 25384

    +

    183P - Progression of central nervous system metastases in advanced non-small cell lung cancer patients effectively treated with first-generation EGFR-TKI (ID 395)

    12:30 - 13:00  |  Author(s): J. Wang
    • Abstract
    • Slides

    Background:
    Central nervous system (CNS) progression is frequently detected in patients with favorable initial responses to first-generation EGFR-TKIs, but data are incomplete with respect to clinical features and prognostic factors of CNS failure in this population.
    
    Methods:
    We retrospectively evaluated 420 advanced non-small cell lung cancer (NSCLC) patients treated with first-generation EGFR-TKI for over 3 months. We analyzed CNS progression of these patients, defining as newly developed CNS metastases or progression of preexisting brain lesions after EGFR-TKI treatment.
    
    Results:
    Of the 420 patients, 99 (23.6%) with CNS progression after EGFR-TKI initiation were identified. The median time to CNS progression was 12 months (95% CI 10.5–13.5). Patients with L858R mutation were more likely to experience CNS failure than those with exon 19 deletion (P = 0.008). For patients with previous brain metastases, the median time to CNS progression of patients with EGFR-TKI and local CNS therapy was significantly longer than those treated with EGFR-TKI alone (14.0 months vs. 11.2 months; P = 0.016). The median survival time after CNS progression was 11.2 months (95% CI 8.8–13.5). L858R mutation, multiple brain metastases progression and CNS with other site failures were negative prognostic factor, while localized CNS therapy was the only significant favorable prognostic factor for overall survival (OS) after CNS progression.
    
    Conclusions:
    For advanced NSCLC patients treated successfully with first-generation EGFR-TKI, careful monitoring for CNS progression should be considered, especially for those with L858R mutation. Localized CNS therapy should be considered for CNS progression.
    
    Clinical trial identification:
    This study was approved by the Institutional Review Board of West China Hospital, Sichuan University and informed consent was obtained from each patient for the use of tissue in molecular analysis
    
    Legal entity responsible for the study:
    West China Hospital, Sichuan UniverWest China Hospital, Sichuan University
    
    Funding:
    Has not received any funding
    
    Disclosure:
    All authors have declared no conflicts of interest.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • 25315

    +

    93P - DNA damage repair protein expression and EGFR gene status in NSCLC (ID 504)

    12:30 - 13:00  |  Presenting Author(s): J. Wang
    • Abstract

    Background:
    Epidermal growth factor receptor (EGFR) is considered to be one of the key driver genes in non-small cell lung cancer (NSCLC). This study explored the potential association between EGFR and DNA damage repair gene expression (Ku70 and Rad51), and their relationship with prognosis in patients with NSCLC.
    
    Methods:
    We reviewed the clinical information of 79 patients. The expression of Ku70 and Rad51 were determined via immunohistochemistry in surgically resected of lung adenocarcinoma and densitometry analysis using image-pro plus 6.0 software. The clinical prognostic value of protein expression was investigated with univariate and multivariate survival analysis.
    
    Results:
    Compared with EGFR mutant patients, mean integral optical density (IOD) of Rad51 and Ku70 had no statistically significant difference in the wild type. Separating patients into low and high expression group according to the median value of IOD, Spearman's test showed no significant correlation between Ku70 and Rad51 expression level and EGFR gene status, while tumor tissue with T1-T2 staging had a lower Ku70 protein expression than T3-T4 (p < 0.05) according to the IOD. No statistical significant difference was found between in mean IOD of Ku70 and Rad51 between recurrence and non-recurrence. Kaplan-Meier analysis revealed that patients with Ku70 low expression tended to have poorer DFS than high expression group (20.6 vs. 22.7 months, p > 0.05). PFS of both Ku70 and Rad51 low expression group had an improving tendency comparing to high expression group (Ku70: 9.0 vs. 6.0 months, and Rad51: 10.0 vs. 7.0 months, both p > 0.05). Multivariate analysis showed, (negative vs. positive) was an independent impact factor of DFS; gender (female vs. male), EGFR status (mutant vs. wild type) and Ku70 expression level (low vs. high) were independent impact factors of PFS.

    Logistic regression between different proteins and possible impact factor
    Protein	Variables	SE	Exp(B)	p
    Ku70	EGFR	0.488	0.684	0.688
    	T-stage	0.833	0.044	0.044
    Rad51	EGFR	0.478	0.925	0.925
    	T-stage	0.732	0.164	0.164

    
    
    Conclusions:
    We provide clinical evidence that Ku70 protein expression level is lower in higher T-stage tumor tissue than the lower. DNA damage repair protein expression level has not been detected to have significant correlation with EGFR gene status and disease recurrence, while tumor high expression level of Ku70 protein might have worse response to systemic therapy. However, further study is required.
    
    Clinical trial identification:
    This is an retrospective study and approve by the clinical trial committee of the hospital.
    
    Legal entity responsible for the study:
    Thoracic Oncology Center, West China Hospital
    
    Funding:
    State Key Laboratory of Biotherapy and Cancer Center of Sichuan province in China
    
    Disclosure:
    All authors have declared no conflicts of interest.